Cleveland Clinic says early studies give BPC-157 some promise but flags unknown risks, especially when it's bought from gray or black market sellers.
Recap by typeshit. Post by Cleveland Clinic on X.
Reuters reports the trend among GLP-1 users is prompting calls for tighter rules on supplements sold alongside the drugs.
A pharmacist account flags two separate Class II recalls involving compounded tirzepatide. Tap through for which products are affected and why.
Health authorities in New South Wales issued a warning after a jump in hospitalisations linked to unapproved peptides sold as wellness products.
A University of Iowa chemist found no peptide in a Brooklyn corner-store vial, and another expert flagged at least 13 bacterial colonies that could cause infection.
8:09
Regan Archibald gives his take on the timeline for retatrutide reaching patients. Tap through for his view on where the drug stands.
Medical Xpress reports a once-weekly triple agonist reduced sleep apnea across two late-stage studies. Tap through for the trial results.
Loading…